Update: Medical treatment of onychomycosis

Dermatologic Therapy

Volumn 25, Issue 6, 2012, Pages 582-593

  Shemer, Avner ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

combined diseases; diagnosis of onychomycosis; onychomycosis; treatment failure; unified criteria for cure

Indexed keywords

ALBACONAZOLE; ALLYLAMINE; AMITRIPTYLINE; AMOROLFINE; BIFONAZOLE; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; DESIPRAMINE; FLUCONAZOLE; GRISEOFULVIN; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; POSACONAZOLE; PRAMICONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; TERBINAFINE; TERFENADINE; THEOPHYLLINE; UREA; VORICONAZOLE; WARFARIN;

ABDOMINAL PAIN; ACREMONIUM; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; ASPERGILLUS; CLINICAL DECISION MAKING; CREAM; CRYPTOCOCCUS NEOFORMANS; DERMATOPHYTE; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRY SKIN; EPIDERMOPHYTON FLOCCOSUM; FEVER; FUSARIUM; GASTROINTESTINAL SYMPTOM; GEL; HAND SURGERY; HEADACHE; HISTOPLASMA CAPSULATUM; HOT FLUSH; HUMAN; HYPERSENSITIVITY; INCIDENCE; LABORATORY TEST; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; NAIL; NAUSEA; NAUSEA AND VOMITING; OINTMENT; ONYCHOMY; ONYCHOMYCOSIS; PERIPHERAL EDEMA; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGNOSIS; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; RISK FACTOR; SAPROTROPH; SCEDOSPORIUM; SCOPULARIOPSIS BREVICAULIS; SEPSIS; SIDE EFFECT; SYSTEMIC THERAPY; TASTE DISORDER; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; URTICARIA; VISUAL DISORDER;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; ONYCHOMYCOSIS; PATIENT SATISFACTION; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870508753     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01551.x     Document Type: Article

References (35)

1. Ramesh V, Reddy B, Singh R,. Onychomycosis. Int J Dermatol 1983: 22 (3): 148-152. (Pubitemid 13116930)
2. Zaias N,. Onychomycosis. Arch Dermatol 1972: 105 (2): 263-274.
3. Elewski BE,. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998: 11 (3): 415-429. (Pubitemid 28379092)
4. Dahdah M, Scher R,. Onychomycosis-an overview. Mycoses 2008: 46 (11-12): 496-505.
5. Elewski BE, Charif MA,. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997: 133: 1172-1173. (Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Data Production Co; 1997:1105-1110). (Pubitemid 27408228)
6. Finch JJ, Warshaw EM,. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007: 20 (1): 31-46. (Pubitemid 46568375)
7. Roberts D, Taylor W, Boyle J,. Guidelines for treatment of onychomycosis. Br J Dermatol 2003: 148 (3): 402-410. (Pubitemid 36461317)
8. Scher RK,. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996: 35: S2-S5.
9. Sigurgeirsson B, Kristinsson KG, Jõnasson PS,. Onychomycosis in icelandic children. J Eur Acad Dermatol Venereol 2006: 20 (7): 796-799. (Pubitemid 44102911)
10. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997: 36: 395-402. (Pubitemid 27131962)
11. Hay RJ, Baran R,. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol 2011: 65 (6): 1219-1227.
12. Shemer A, Trau H, Davidovici B, Grunwald MH, Amichai B,. Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail. J Dtsch Dermatol Ges 2007: 5 (12): 1108-1111. (Pubitemid 350239468)
13. Shemer A, Trau H, Davidovici B, Grunwald M, Amichai B,. Collection of fungi samples from nails: comparative study of curettage and drilling techniques. J Eur Acad Dermatol Venereol 2008: 22 (2): 182-185.
14. Daniel CR 3rd,. The diagnosis of nail fungal infection. Arch Dermatol 1991: 127 (10): 1566-1567.
15. Gupta AK, Ryder J, Summerbell RC,. Comparison of efficacy criteria across onychomycosis trials: need for standardization. Int J Dermatol 2003: 42: 312-315. (Pubitemid 36553233)
16. Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007: 56 (6): 939-944. (Pubitemid 46729696)
17. Scher R, Baran R,. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003: 149: 5-9. (Pubitemid 37410064)
18. Yang D, Michel L, Chaumont JP, Millet-Clerc J,. Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis. Mycopathologia 2000: 148 (2): 79-82. (Pubitemid 32044914)
19. Carney C, Tosti A, Daniel R, et al. A new classification system for grading the severity of onychomycosis: onychomycosis severity index. Arch Dermatol 2011: 147 (11): 1277.
20. Shemer A, Nathansohn N, Trau H,. Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis. J Eur Acad Dermatol Venereol 2006: 20 (10): 1194-1196.
21. Shemer A, Davidovici B, Grunwald M, Trau H, Amichai B,. New criteria for the laboratory diagnosis of nondermatophyte moulds in onychomycosis. Br J Dermatol 2009: 160 (1): 37-39.
22. Friedman-Birnbaum R, Cohen A, Shemer A, Bitterman O, Bergman R, Stettendorf S,. Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int J Dermatol 1997: 36 (1): 67-69. (Pubitemid 27139760)
23. Baran R, Kaoukhov A,. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005: 19 (1): 21-29. (Pubitemid 40268136)
24. Gupta A, Ryder J, Johnson A,. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004: 150 (3): 537-544. (Pubitemid 38446311)
25. Gupta AK, Katz HI, Shear NH,. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 1999: 41 (2): 237-249. (Pubitemid 29379711)
26. Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil®) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Br J Dermatol 1999: 141: 5-14.
27. van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992: 126 (Suppl 39): 36-39.
28. Welsh O, Vera-Cabrera L, Welsh E,. Onychomycosis. Clin Dermatol 2010: 28 (2): 151-159.
29. Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A,. A randomised, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2010: 166 (2): 389-398.
30. Gupta A, Leonardi C, Stoltz R, Pierce P, Conetta B,. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005: 19 (4): 437-443. (Pubitemid 40946096)
31. Thompson GR 3rd, Wiederhold NP,. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010: 170 (5): 291-313.
32. Geria AN, Scheinfeld NS,. Pramiconazole, a triazole compound for the treatment of fungal infections. IDrugs 2008: 11 (9): 661-670.
33. Bartroli J, Merlos M,. Overview of albaconazole. Eur Infect Dis 2011: 5 (2): 88-91.
34. Hay R, Mackie R, Clayton Y,. Tioconazole nail solution-an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985: 10 (2): 111-115. (Pubitemid 15125434)
35. Baran R, Hay R, Haneke E, et al. Onychomycosis: the Current Approach to Diagnosis and Therapy, 2nd edn. Oxford: Taylor and Francis, 2006.